Plasma Concentrations of Isoniazid and Rifampin Are Decreased in Adult Pulmonary Tuberculosis Patients with Diabetes Mellitus
Authors:
Open Access
- 1 November 2013
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 57 (11) , 5740-5742
Abstract
Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% ( P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% ( P < 0.01), 66% or 100% ( P < 0.05), 30% or 50% ( P = 0.198), and 32% or 21% ( P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.Keywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIVAntimicrobial Agents and Chemotherapy, 2012
- Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort studyBMJ Open, 2012
- Effect of Type 2 Diabetes Mellitus on the Clinical Severity and Treatment Outcome in Patients With Pulmonary Tuberculosis: A Potential Role in the Emergence of Multidrug-resistanceJournal of the Formosan Medical Association, 2011
- Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USAEmerging Infectious Diseases, 2010
- Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 DiabetesAntimicrobial Agents and Chemotherapy, 2010
- Type 2 diabetes and multidrug-resistant tuberculosisScandinavian Journal of Infectious Diseases, 2008
- Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidenceBMC Public Health, 2007
- The Effect of Type 2 Diabetes Mellitus on the Presentation and Treatment Response of Pulmonary TuberculosisClinical Infectious Diseases, 2007
- Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 DiabetesClinical Infectious Diseases, 2006
- Therapeutic Monitoring of Isoniazid, Pyrazinamide and Rifampicin in Tuberculosis Patients Using LCChromatographia, 2005